Veracyte Balance Sheet Health
Financial Health criteria checks 6/6
Veracyte has a total shareholder equity of $1.2B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.3B and $99.0M respectively. Veracyte's EBIT is $20.5M making its interest coverage ratio -1.8. It has cash and short-term investments of $274.1M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -1.8x |
| Cash | US$274.08m |
| Equity | US$1.18b |
| Total liabilities | US$98.98m |
| Total assets | US$1.28b |
Recent financial health updates
No updates
Recent updates
Veracyte: Getting Frothy
Dec 11Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Dec 01
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Aug 18Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Jul 02Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Jun 06Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 09Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S
Apr 18A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)
Mar 18Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk
Jul 13Veracyte: Not A Healthy Diagnosis
May 12Financial Position Analysis
Short Term Liabilities: VCYT's short term assets ($356.9M) exceed its short term liabilities ($70.3M).
Long Term Liabilities: VCYT's short term assets ($356.9M) exceed its long term liabilities ($28.7M).
Debt to Equity History and Analysis
Debt Level: VCYT is debt free.
Reducing Debt: VCYT has no debt compared to 5 years ago when its debt to equity ratio was 0.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable VCYT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: VCYT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 45.6% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:10 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Veracyte, Inc. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung Ji Nam | BTIG |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |
| Matthew Sykes | Goldman Sachs |